Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways

Mitsuho Imai-Sumida, Takeshi Chiyomaru, Shahana Majid, Sharanjot Saini, Hannah Nip, Rajvir Dahiya, Yuichiro Tanaka, Soichiro Yamamura

Research output: Contribution to journalArticle

Abstract

Silibinin is the major active constituent of silymarin, an extract of milk thistle seeds. Silibinin has been shown to have significant anti-cancer effects in a variety of malignancies. However, the molecular mechanisms of silibinin action in bladder cancer have not been studied extensively. In the present study, we found that silibinin (10 μM) significantly suppressed proliferation, migration, invasion and induced apoptosis of T24 and UM-UC-3 human bladder cancer cells. Silibinin down-regulated the actin cytoskeleton and phosphatidylinositide 3-kinase (PI3K)/Akt signaling pathways in these cancer cell lines. These pathways were found to crosstalk through RAS cascades. We found that silibinin suppressed levels of trimethylated histone H3 lysine 4 and acetylated H3 at the KRAS promoter. Furthermore, silibinin targets long non-coding RNA: HOTAIR and ZFAS1, which are known to play roles as oncogenic factors in various cancers. This study shows that silibinin exerts anti-cancer effects through down-regulation of actin cytoskeleton and PI3K/Akt pathways and thus suppresses bladder cancer growth and progression.

Original languageEnglish (US)
Pages (from-to)92032-92042
Number of pages11
JournalOncotarget
Volume8
Issue number54
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Actin Cytoskeleton
Urinary Bladder Neoplasms
Phosphotransferases
Down-Regulation
Neoplasms
Milk Thistle
Long Noncoding RNA
Silymarin
silybin
Histones
Lysine
Seeds
Apoptosis
Cell Line
Growth

Keywords

  • Bladder cancer
  • KRAS
  • Long non-coding RNA
  • PI3K
  • Silibinin

ASJC Scopus subject areas

  • Oncology

Cite this

Imai-Sumida, M., Chiyomaru, T., Majid, S., Saini, S., Nip, H., Dahiya, R., ... Yamamura, S. (2017). Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways. Oncotarget, 8(54), 92032-92042. https://doi.org/10.18632/oncotarget.20734

Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways. / Imai-Sumida, Mitsuho; Chiyomaru, Takeshi; Majid, Shahana; Saini, Sharanjot; Nip, Hannah; Dahiya, Rajvir; Tanaka, Yuichiro; Yamamura, Soichiro.

In: Oncotarget, Vol. 8, No. 54, 01.01.2017, p. 92032-92042.

Research output: Contribution to journalArticle

Imai-Sumida, M, Chiyomaru, T, Majid, S, Saini, S, Nip, H, Dahiya, R, Tanaka, Y & Yamamura, S 2017, 'Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways', Oncotarget, vol. 8, no. 54, pp. 92032-92042. https://doi.org/10.18632/oncotarget.20734
Imai-Sumida, Mitsuho ; Chiyomaru, Takeshi ; Majid, Shahana ; Saini, Sharanjot ; Nip, Hannah ; Dahiya, Rajvir ; Tanaka, Yuichiro ; Yamamura, Soichiro. / Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways. In: Oncotarget. 2017 ; Vol. 8, No. 54. pp. 92032-92042.
@article{160e1e8f510d4dceb1eac3db51228442,
title = "Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways",
abstract = "Silibinin is the major active constituent of silymarin, an extract of milk thistle seeds. Silibinin has been shown to have significant anti-cancer effects in a variety of malignancies. However, the molecular mechanisms of silibinin action in bladder cancer have not been studied extensively. In the present study, we found that silibinin (10 μM) significantly suppressed proliferation, migration, invasion and induced apoptosis of T24 and UM-UC-3 human bladder cancer cells. Silibinin down-regulated the actin cytoskeleton and phosphatidylinositide 3-kinase (PI3K)/Akt signaling pathways in these cancer cell lines. These pathways were found to crosstalk through RAS cascades. We found that silibinin suppressed levels of trimethylated histone H3 lysine 4 and acetylated H3 at the KRAS promoter. Furthermore, silibinin targets long non-coding RNA: HOTAIR and ZFAS1, which are known to play roles as oncogenic factors in various cancers. This study shows that silibinin exerts anti-cancer effects through down-regulation of actin cytoskeleton and PI3K/Akt pathways and thus suppresses bladder cancer growth and progression.",
keywords = "Bladder cancer, KRAS, Long non-coding RNA, PI3K, Silibinin",
author = "Mitsuho Imai-Sumida and Takeshi Chiyomaru and Shahana Majid and Sharanjot Saini and Hannah Nip and Rajvir Dahiya and Yuichiro Tanaka and Soichiro Yamamura",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.20734",
language = "English (US)",
volume = "8",
pages = "92032--92042",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "54",

}

TY - JOUR

T1 - Silibinin suppresses bladder cancer through down-regulation of actin cytoskeleton and PI3K/Akt signaling pathways

AU - Imai-Sumida, Mitsuho

AU - Chiyomaru, Takeshi

AU - Majid, Shahana

AU - Saini, Sharanjot

AU - Nip, Hannah

AU - Dahiya, Rajvir

AU - Tanaka, Yuichiro

AU - Yamamura, Soichiro

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Silibinin is the major active constituent of silymarin, an extract of milk thistle seeds. Silibinin has been shown to have significant anti-cancer effects in a variety of malignancies. However, the molecular mechanisms of silibinin action in bladder cancer have not been studied extensively. In the present study, we found that silibinin (10 μM) significantly suppressed proliferation, migration, invasion and induced apoptosis of T24 and UM-UC-3 human bladder cancer cells. Silibinin down-regulated the actin cytoskeleton and phosphatidylinositide 3-kinase (PI3K)/Akt signaling pathways in these cancer cell lines. These pathways were found to crosstalk through RAS cascades. We found that silibinin suppressed levels of trimethylated histone H3 lysine 4 and acetylated H3 at the KRAS promoter. Furthermore, silibinin targets long non-coding RNA: HOTAIR and ZFAS1, which are known to play roles as oncogenic factors in various cancers. This study shows that silibinin exerts anti-cancer effects through down-regulation of actin cytoskeleton and PI3K/Akt pathways and thus suppresses bladder cancer growth and progression.

AB - Silibinin is the major active constituent of silymarin, an extract of milk thistle seeds. Silibinin has been shown to have significant anti-cancer effects in a variety of malignancies. However, the molecular mechanisms of silibinin action in bladder cancer have not been studied extensively. In the present study, we found that silibinin (10 μM) significantly suppressed proliferation, migration, invasion and induced apoptosis of T24 and UM-UC-3 human bladder cancer cells. Silibinin down-regulated the actin cytoskeleton and phosphatidylinositide 3-kinase (PI3K)/Akt signaling pathways in these cancer cell lines. These pathways were found to crosstalk through RAS cascades. We found that silibinin suppressed levels of trimethylated histone H3 lysine 4 and acetylated H3 at the KRAS promoter. Furthermore, silibinin targets long non-coding RNA: HOTAIR and ZFAS1, which are known to play roles as oncogenic factors in various cancers. This study shows that silibinin exerts anti-cancer effects through down-regulation of actin cytoskeleton and PI3K/Akt pathways and thus suppresses bladder cancer growth and progression.

KW - Bladder cancer

KW - KRAS

KW - Long non-coding RNA

KW - PI3K

KW - Silibinin

UR - http://www.scopus.com/inward/record.url?scp=85032686077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032686077&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20734

DO - 10.18632/oncotarget.20734

M3 - Article

AN - SCOPUS:85032686077

VL - 8

SP - 92032

EP - 92042

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 54

ER -